Jin Medical International Ltd (ZJYL) Fair Value & Analysis
Healthcare · US · Market cap $19.3M
Jin Medical International Ltd
ZJYL · US
Fair value as of: Jul 25, 2026
From 12 valuation models · updated 16 days ago
Share price +12.6% over the past month.
Below-average quality, screening 38% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (29/100). That raises the risk this is a value trap rather than a bargain.
- A fairly wide model range ($2.03 to $3.71) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.
How to read this chart
40‑month range $1.82 – $276.11 · fair‑value band $2.03 – $3.71 · the $2.15 price screens below the $2.97 fair value. Dashed = 300-day average. As of Jul 25, 2026.
Analysis
Jin Medical International Ltd (ZJYL) currently trades at $2.15, while our model-based Fair Value estimate is $2.97, implying the stock looks roughly 38.1% undervalued today. The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Jin Medical International Ltd generated revenue of $20.7M at a net margin of 5.8%. Revenue declined 16.5% year over year. It earns a return on equity of 4.8%. Net debt stands at $11.4M. Fundamentals as of Jul 25, 2026
Our scenario range runs from $2.03 (bear case) to $3.71 (bull case); at $2.15, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 38%, ZJYL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: Multiples ($2.97) versus Earnings-Based ($1.47). Highest evidence: Growth-Adj P/E (68).
Notify me when ZJYL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 8
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids for people with disabilities, the elderly, and people recovering from injury.
Full company description
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids for people with disabilities, the elderly, and people recovering from injury. The company offers wheelchairs and wheelchair components, such as wheels and brakes; oxygen concentrators, bath aids, and rehabilitative devices, as well as infrastructures for shared wheelchairs and other shared health products; oxygen chambers and beauty instruments; and shampoo instruments and nano thermal therapy chambers. It operates in the Mainland China, Japan, the United States, Hong Kong, Singapore, Korea, Australia, and internationally. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. operates as a subsidiary of Jolly Harmony Enterprises Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jin Medical International Ltd reported revenue of $20.7M in FY2025 versus $20.8M in FY2021, a compound −0.1%/yr. Reported net income was $1.2M in FY2025, compounding −18.0%/yr from FY2021.
Watch ZJYL: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Jin Medical International Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jin Medical International Ltd (ZJYL) overvalued or undervalued?
What is the fair value of ZJYL?
What is the quality score of ZJYL?
What is the revenue of Jin Medical International Ltd (ZJYL)?
What is the net profit margin of ZJYL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jin Medical International Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.